Effects of Remote Ischaemic Preconditioning on the Internal Thoracic Artery Nitric Oxide Synthase Isoforms in Patients Undergoing Coronary Artery Bypass Grafting.
coronary artery graft
internal thoracic artery
nitric oxide synthase isoforms
remote ischaemic preconditioning
Journal
Antioxidants (Basel, Switzerland)
ISSN: 2076-3921
Titre abrégé: Antioxidants (Basel)
Pays: Switzerland
ID NLM: 101668981
Informations de publication
Date de publication:
29 Nov 2021
29 Nov 2021
Historique:
received:
11
10
2021
revised:
25
11
2021
accepted:
26
11
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
25
12
2021
Statut:
epublish
Résumé
Remote ischaemic preconditioning (RIPC) is a medical procedure that consists of repeated brief periods of transient ischaemia and reperfusion of distant organs (limbs) with the ability to provide internal organ protection from ischaemia. Even though RIPC has been successfully applied in patients with myocardial infarction during coronary revascularization (surgery/percutaneous angioplasty), the underlying molecular mechanisms are yet to be clarified. Thus, our study aimed to determine the role of nitric oxide synthase (NOS) isoforms in RIPC-induced protection (3 × 5 min of forearm ischaemia with 5 min of reperfusion) of arterial graft in patients undergoing urgent coronary artery bypass grafting (CABG). We examined RIPC effects on specific expression and immunolocalization of three NOS isoforms - endothelial (eNOS), inducible (iNOS) and neuronal (nNOS) in patients' internal thoracic artery (ITA) used as a graft. We found that the application of RIPC protocol leads to an increased protein expression of eNOS, which was further confirmed with strong eNOS immunopositivity, especially in the endothelium and smooth muscle cells of ITA. The same analysis of two other NOS isoforms, iNOS and nNOS, showed no significant differences between patients undergoing CABG with or without RIPC. Our results demonstrate RIPC-induced upregulation of eNOS in human ITA, pointing to its significance in achieving protective phenotype on a systemic level with important implications for graft patency.
Identifiants
pubmed: 34943013
pii: antiox10121910
doi: 10.3390/antiox10121910
pmc: PMC8750270
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministry of Education, Science and Technological Development of the Republic of Serbia
ID : 451-03-9/2021-14/ 200007
Organisme : Ministry of Education, Science and Technological Development of the Republic of Serbia
ID : 451-03-9/2021-14/ 200178.
Références
Life Sci. 2016 Apr 15;151:250-258
pubmed: 26979771
Pharmacol Res. 2000 Apr;41(4):493-6
pubmed: 10704275
Am J Physiol. 1995 Dec;269(6 Pt 1):C1371-8
pubmed: 8572165
Anesth Analg. 2013 Oct;117(4):891-901
pubmed: 23960036
Adv Exp Med Biol. 2017;982:335-346
pubmed: 28551796
Acta Cardiol. 2003 Apr;58(2):119-32
pubmed: 12715903
J Cardiovasc Pharmacol Ther. 2011 Sep-Dec;16(3-4):255-9
pubmed: 21821525
Neurosci Behav Physiol. 2005 Jul;35(6):567-72
pubmed: 16342612
Pflugers Arch. 2017 Feb;469(2):159-181
pubmed: 27928644
Nitric Oxide. 2001 Aug;5(4):317-33
pubmed: 11485370
Free Radic Biol Med. 2021 Feb 1;163:325-343
pubmed: 33359685
Int Rev Cell Mol Biol. 2012;298:229-317
pubmed: 22878108
Clin Sci (Lond). 2011 Sep;121(6):257-66
pubmed: 21463257
J Biol Chem. 1996 Jun 21;271(25):15069-73
pubmed: 8663208
Can J Physiol Pharmacol. 2012 Jun;90(6):713-38
pubmed: 22625870
J Am Heart Assoc. 2018 Oct 2;7(19):e009058
pubmed: 30371329
J Thorac Cardiovasc Surg. 2006 Nov;132(5):1131-6
pubmed: 17059934
Cardiovasc Res. 2002 Feb 1;53(2):405-13
pubmed: 11827691
Br J Anaesth. 2016 Sep;117 Suppl 2:ii44-ii62
pubmed: 27566808
Am J Physiol. 1999 May;276(5):H1567-73
pubmed: 10330240
Circulation. 2000 Jun 13;101(23):2742-8
pubmed: 10851213
Cardiovasc Res. 2008 Aug 1;79(3):377-86
pubmed: 18456674
Cell Physiol Biochem. 2018;46(4):1650-1667
pubmed: 29694958
Front Physiol. 2012 Feb 20;3:27
pubmed: 22363297
J Thorac Cardiovasc Surg. 2003 Jun;125(6):1510-5
pubmed: 12830073
Transplantation. 2007 Aug 27;84(4):445-58
pubmed: 17713425
Gen Physiol Biophys. 2005 Dec;24(4):411-26
pubmed: 16474186
Eur J Pharmacol. 2015 Jan 5;746:317-32
pubmed: 25176179
Exp Physiol. 2016 Jun 1;101(6):708-16
pubmed: 27028009
FASEB J. 2002 Apr;16(6):500-8
pubmed: 11919152
Lab Invest. 2004 Feb;84(2):182-90
pubmed: 14661033
Circ Res. 2014 May 9;114(10):1601-10
pubmed: 24643960
Biochem Pharmacol. 1989 Jun 1;38(11):1709-15
pubmed: 2567594
J Physiol Pharmacol. 2010 Feb;61(1):21-7
pubmed: 20228411
J Surg Res. 2008 Dec;150(2):304-30
pubmed: 19040966
J Exp Biol. 2005 Nov;208(Pt 22):4263-71
pubmed: 16272249
J Am Coll Cardiol. 2005 Aug 2;46(3):450-6
pubmed: 16053957
Ann Plast Surg. 2017 Oct;79(4):e25-e29
pubmed: 24691313
Int J Cardiol. 2018 Feb 1;252:24-30
pubmed: 29249435
Circulation. 2001 Sep 18;104(12 Suppl 1):I344-9
pubmed: 11568080
Circ Res. 2003 Nov 14;93(10):907-16
pubmed: 14615494
Trends Endocrinol Metab. 2009 Aug;20(6):295-302
pubmed: 19647446
Oncotarget. 2019 Jan 4;10(2):216-244
pubmed: 30719216
Microsurgery. 2002;22(6):227-31
pubmed: 12375287
Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):405-12
pubmed: 14656742
Circulation. 2002 Dec 3;106(23):2881-3
pubmed: 12460865
Chin Med J (Engl). 2011 Jul;124(14):2209-15
pubmed: 21933628
Cardiovasc Res. 2003 Jan;57(1):55-62
pubmed: 12504814
Cardiovasc Drugs Ther. 2015 Dec;29(6):573-588
pubmed: 26477661
Mol Cell Biochem. 1996 Jul-Aug;160-161:265-71
pubmed: 8901482